Explore the efficacy and possible side effects of capmatinib

Capmatinib is a highly selective MET inhibitor specifically designed to treat patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations (METex14). MET gene mutations can lead to abnormal cell signaling, thereby promoting the proliferation and metastasis of cancer cells. Capmatinib blocks the transmission of abnormal signals by targeting MET tyrosine kinase, limiting the growth of tumor cells and thereby delaying disease progression.

In clinical trials, capmatinib has shown significant efficacy, especially in treatment-naive patients who have not received any treatment, the objective response rate (ORR) can reach more than 60%, and for patients who have received previous treatment, the ORR can also reach 40%-50%. In addition, capmatinib also shows good efficacy in patients with brain metastases, can penetrate the blood-brain barrier, and helps control metastatic lesions in the central nervous system. This makes it an important treatment option for patients with MET-mutated NSCLC.

However, capmatinib may also cause some side effects during treatment. The most common adverse reactions include nausea, vomiting, decreased appetite, diarrhea, elevated transaminases, and edema. In addition, some patients may develop interstitial lung disease (ILD) or pneumonia, so patients' lung health needs to be closely monitored during treatment. If the patient develops shortness of breath or persistent cough, the drug should be discontinued immediately and appropriate medical intervention should be carried out. A small number of patients may experience skin photosensitivity reactions, so sun protection is recommended during treatment.

Overall, capmatinib was relatively well tolerated and its side effects were manageable, but close monitoring by physicians is still required to ensure patient safety and optimize treatment efficacy.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib